Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to 61.84%.

  • Ironwood Pharmaceuticals' EBIT Margin rose 338500.0% to 61.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 36.34%, marking a year-over-year increase of 101200.0%. This contributed to the annual value of 26.5% for FY2024, which is 2400400.0% up from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its EBIT Margin stood at 61.84% for Q3 2025, which was up 338500.0% from 53.17% recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' EBIT Margin ranged from a high of 63.77% in Q4 2022 and a low of 1008.68% during Q2 2023
  • For the 5-year period, Ironwood Pharmaceuticals' EBIT Margin averaged around 14.07%, with its median value being 51.1% (2021).
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' EBIT Margin plummeted by -10659200bps in 2023, and later surged by 10351400bps in 2024.
  • Ironwood Pharmaceuticals' EBIT Margin (Quarter) stood at 48.32% in 2021, then soared by 32bps to 63.77% in 2022, then tumbled by -50bps to 31.98% in 2023, then increased by 9bps to 34.78% in 2024, then skyrocketed by 78bps to 61.84% in 2025.
  • Its EBIT Margin was 61.84% in Q3 2025, compared to 53.17% in Q2 2025 and 70.75% in Q1 2025.